LABU 📈 Direxion Daily S&P Biotech - Overview
Exchange: NYSE ARCA • Country: USA • Currency: USD • Type: Etf • ISIN: US25490K3234 • Trading--Leveraged Equity
LABU: Biotechnology, Pharmaceuticals, Medical, Healthcare, Research
The fund, under normal circumstances, invests at least 80% of its net assets in financial instruments, such as swap agreements, securities of the index, and ETFs that track the index, that, in combination, provide 3X daily leveraged exposure to the index, consistent with the fund's investment objective. The index is designed to measure the performance of the biotechnology sub-industry based on the Global Industry Classification Standards (GICS). The fund is non-diversified. ‣ Company URL: http://www.direxionfunds.com ‣ Domicile: United States
Additional Sources for LABU ETF
News:
Wall Street Journal
Benzinga
Yahoo Finance
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
Tweets: X Stocktwits
Fund Manager Positions: Dataroma Stockcircle
LABU ETF Overview
| Market Cap in USD | 857m |
| Category | Trading--Leveraged Equity |
| TER | 0.96% |
| IPO / Inception | 2015-05-28 |
LABU ETF Ratings
| Growth 5y | -79.0% |
| Fundamental | - |
| Dividend | 1.96% |
| Rel. Strength Industry | -114 |
| Analysts | - |
| Fair Price Momentum | 58.58 USD |
| Fair Price DCF | - |
LABU Dividends
| Dividend Yield 12m | 0.33% |
| Yield on Cost 5y | 0.03% |
| Annual Growth 5y | -33.31% |
| Payout Consistency | 46.7% |
LABU Growth Ratios
| Growth Correlation 3m | -53.8% |
| Growth Correlation 12m | 4.4% |
| Growth Correlation 5y | -82% |
| CAGR 5y | -40.18% |
| CAGR/Mean DD 5y | -0.55 |
| Sharpe Ratio 12m | 0.06 |
| Alpha | -90.76 |
| Beta | 3.15 |
| Volatility | 102.27% |
| Current Volume | 1278.8k |
| Average Volume 20d | 1131.6k |
What is the price of LABU stocks?
As of December 22, 2024, the stock is trading at USD 94.24 with a total of 1,278,811 shares traded.
Over the past week, the price has changed by -7.71%, over one month by -11.09%, over three months by -32.80% and over the past year by -3.73%.
As of December 22, 2024, the stock is trading at USD 94.24 with a total of 1,278,811 shares traded.
Over the past week, the price has changed by -7.71%, over one month by -11.09%, over three months by -32.80% and over the past year by -3.73%.
Is Direxion Daily S&P Biotech a good stock to buy?
No, based on ValueRay Analyses, Direxion Daily S&P Biotech (NYSE ARCA:LABU) is currently (December 2024) a stock to sell. It has a ValueRay Growth Rating of -78.95 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LABU as of December 2024 is 58.58. This means that LABU is currently overvalued and has a potential downside of -37.84%.
No, based on ValueRay Analyses, Direxion Daily S&P Biotech (NYSE ARCA:LABU) is currently (December 2024) a stock to sell. It has a ValueRay Growth Rating of -78.95 and therefor a clear technical negative rating according to historical growth.
Based on ValueRays Analyses, Dividends and Discounted-Cash-Flow, the Fair Value of LABU as of December 2024 is 58.58. This means that LABU is currently overvalued and has a potential downside of -37.84%.
Is LABU a buy, sell or hold?
Direxion Daily S&P Biotech has no consensus analysts rating.
Direxion Daily S&P Biotech has no consensus analysts rating.
What are the forecast for LABU stock price target?
According to ValueRays Forecast Model, LABU Direxion Daily S&P Biotech will be worth about 69.6 in December 2025. The stock is currently trading at 94.24. This means that the stock has a potential downside of -26.19%.
According to ValueRays Forecast Model, LABU Direxion Daily S&P Biotech will be worth about 69.6 in December 2025. The stock is currently trading at 94.24. This means that the stock has a potential downside of -26.19%.
| Issuer | Forecast | Upside |
|---|---|---|
| Wallstreet Target Price | - | - |
| Analysts Target Price | - | - |
| ValueRay Target Price | 69.6 | -26.2% |